“Lebrikizumab Improves Atopic Dermatitis and ​Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: ​ Results From the ADapt Trial”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 1, Jan. 2025, p. s512, https://doi.org/10.25251/skin.9.supp.512.